This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
356
Change from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D) total score at week 8, Last Observation Carried Forward.
CGI, HAM-A, QUIDS, SDS, MOS-12 Sleep Module, LSEQ, Safety and Tolerability, PK/PD
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Smyrna, Georgia, United States
...and 21 more locations